comparemela.com

Nikhil Munshi News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sixth Indian Myeloma Congress at Symbiosis Medical College for Women from January 12-14, 2024 | Pune News

The conference featured international experts in Myeloma, including Dr. Nikhil Munshi, Dr. Priya Sampathkumar, Dr. Prashant Kapoor, Dr. Amit Khot, Dr.

Amit khotPrashant kapoorDipti talaulikarPreena nairTapan saikiaVincent rajkumarNikhil munshiPriya sampathkumarIndian myeloma congressInternational observershipSymbiosis medical college for womenDana farber cancer instituteNational expertsHarward medical schoolIndian myeloma academic groupeSymbiosis medical college

6th Indian Myeloma Congress begins at Symbiosis Medical College for Women

Around 104 research works done from various parts of the country will be presented at this conference.

Amit khotGen ma tutakneVincent rajkumarPrashant kapoorVijay sagarDipti talaulikarNikhil munshiPriya sampathkumarDana farber cancer instituteDean of the medical collegeHarvard medical schoolNational expertsExtending survivalMayo clinicIndian myeloma congressTh indian myeloma congress

Time to Stop Routine Maintenance Therapy in Myeloma?

Physicians may need to rethink maintenance with lenalidomide (Revlimid and generics) for multiple myeloma.

United statesNew yorkMemorial sloan kettering cancer centerNikhil munshiSergio giraltBenjamin dermanShaji kumarInternational myeloma working groupUniversity of alabama at birminghamUniversity of chicagoNational comprehensive cancer network multiple myeloma guidelinesHarvard medical schoolLancet haematologyLuciano costaNew england journalMayo clinic

Teclistamab for MM: Lifesaver or Cause of Death ?

Teclistamab (Tecvayli) has been approved for relapsed/refractory multiple myeloma patients who have received at least four lines of therapy; typically, such patients have just a few weeks to live.

South carolinaUnited statesNew yorkMemorial sloan kettering cancer centerSaad usmaniNikhil munshiKashyap patelBristol myers squibbDrug administrationHarvard medical schoolCommunity oncology allianceCarolina medicaidpt committeeJanssen biotechNew england journalCommunity oncologySeattle genetics

2seventy bio Announces Plans to Initiate KarMMa-9 Study of Abecma (idecabtagene vicleucel) in Newly Diagnosed Multiple Myeloma Patients

07.09.2022 - 2seventy bio, Inc. (Nasdaq: TSVT) today announced plans to initiate the KarMMa-9 study to evaluate Abecma (idecabtagene vicleucel) in newly diagnosed multiple myeloma patients who have suboptimal response to transplant. The company, in partnership .

United statesHemophagocytic lymphohistiocytosisNikhil munshiAmerican society of clinical oncologyJerome lipper multiple myeloma centerDrug administrationHarvard medical schoolMyeloma cell therapy consortiumExchange commissionBristol myers squibbDana farber cancer instituteCorrelative scienceKraft family chairDana farber cancerHarvard medicalClinical oncology

vimarsana © 2020. All Rights Reserved.